Form 4: Richard Ian Griffiths Reports Beneficial Ownership Change in Silence Therapeutics plc

Director Richard Ian Griffiths reports changes in beneficial ownership of Silence Therapeutics plc shares through recent transactions.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, filed a Form 4 detailing changes in beneficial ownership.
• On May 5, 2025, Griffiths acquired 100,000 American Depositary Shares (ADS) at $3.94 each, convertible into 300,000 ordinary shares.
• On May 6, 2025, Griffiths acquired 100,000 ADS at $3.96 each, convertible into 300,000 ordinary shares.
• On May 7, 2025, Griffiths acquired 50,000 ADS at $3.81 each, convertible into 150,000 ordinary shares.
• Following these transactions, Griffiths directly owns 10,970,853 ordinary shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of share transactions. The director's increased holding could be seen as a positive signal, but it's not definitive.

Positives

• Director's increased stake may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be informative for investors.

Stakeholder Impact

• The change in ownership may influence investor sentiment.

Key Dates

Keywords

Silence Therapeutics, Griffiths, Beneficial Ownership, Form 4, ADS, Ordinary Shares, Director, Transaction